News
Why Midmarket Sponsors Struggle with Transparency and What They Can Do
April 26th 2019Transparency in clinical trials doesn't have to be difficult but requires attention writes Thomas Wicks, Chief Strategy Officer for TrialScope. Smaller organizations tend to lag in their commitments to clinical data sharing and be non-compliant with regulations, but the trend is shifting.
Chemotherapy Development is ‘In’ Again
April 23rd 2019Cancer therapy development has advanced to researching targeted immunotherapies and moving into gene-specific therapies. Some companies, however, are focusing on reviving cytotoxic therapies that were too toxic for patients when administered generally. Bill Newell, Chief Executive Officer of Sutro Biopharma, sits down with Moe Alsumidaie to discuss the use of a cell-free protein synthesis approach.
Understanding the Statistical Implications of Undetected Risk
April 22nd 2019Nonadherence in clinical trials plays a significant role in influencing the quality of data, trial results and, subsequently trial cost and duration. It may stem from unintentional drivers, such as forgetfulness, poor organizational skills, protocol regimen complexity, or experiencing an Adverse Event.
